Predictive value of the sFlt‑1/PlGF ratio in women with suspected preeclampsia: An update (Review)
- Authors:
- Alexandros Velegrakis
- Elisavet Kouvidi
- Persefoni Fragkiadaki
- Stavros Sifakis
-
Affiliations: Department of Obstetrics and Gynecology, University Hospital of Heraklion, 71500 Heraklion, Greece, Genesis Genoma Lab, Genetic Diagnosis, Clinical Genetics and Research, 15232 Athens, Greece, Laboratory of Toxicology, Medical School, University of Crete, 71003 Heraklion, Greece, Euromedica Mitera Kritis, 71202 Heraklion, Greece - Published online on: August 9, 2023 https://doi.org/10.3892/ijmm.2023.5292
- Article Number: 89
-
Copyright: © Velegrakis et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Troiano NH: Physiologic and hemodynamic changes during pregnancy. AACN Adv Crit Care. 29:273–283. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sierra-Laguado J, Garcia RG and López-Jaramillo P: Flow-mediated dilatation of the brachial artery in pregnancy. Int J Gynaecol Obstet. 93:60–61. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Cid M and González M: Potential benefits of physical activity during pregnancy for the reduction of gestational diabetes prevalence and oxidative stress. Early Hum Dev. 94:57–62. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sibai BM and Frangieh A: Maternal adaptation to pregnancy. Curr Opin Obstet Gynecol. 7:420–426. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmed A and Perkins J: Angiogenesis and intrauterine growth restriction. Baillieres Best Pract Res Clin Obstet Gynaecol. 14:981–998. 2000. View Article : Google Scholar | |
|
Vrachnis N, Kalampokas E, Sifakis S, Vitoratos N, Kalampokas T, Botsis D and Iliodromiti Z: Placental growth factor (PlGF): A key to optimizing fetal growth. J Matern Fetal Neonatal Med. 26:995–1002. 2013. View Article : Google Scholar | |
|
Sibai B, Dekker G and Kupferminc M: Pre-eclampsia. Lancet. 365:785–799. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
No authors listed. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. 135:e237–e260. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G and Ishaku S; International Society for the Study of Hypertension in Pregnancy (ISSHP): The hypertensive disorders of pregnancy: ISSHP classification, diagnosis and management recommendations for international practice. Hypertension. 72:24–43. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Xiong X, Demianczuk NN, Saunders LD, Wang FL and Fraser WD: Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol. 155:203–209. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Staff AC: The two-stage placental model of preeclampsia: An update. J Reprod Immunol. 134-135:1–10. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Redman CW: Current topic: pre-eclampsia and the placenta. Placenta. 12:301–308. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Pankiewicz K, Szczerba E, Fijalkowska A, Szamotulska K, Szewczyk G, Issat T and Maciejewski TM: The association between serum galectin-3 level and its placental production in patients with preeclampsia. J Physiol Pharmacol. 71:845–856. 2020. | |
|
Redman CWG and Staff AC: Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol. 213(Suppl 4): S9.e1–S9.e4. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Maynard SE, Venkatesha S, Thadhani R and Karumanchi SA: Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res. 57:1R–7R. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O and Taketani Y: Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab. 88:2348–2351. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Tsatsaris V, Goffin F and Foidart JM: Circulating angiogenic factors and preeclampsia. N Engl J Med. 350:2003–2004. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, et al: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 350:672–683. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Maynard SE and Karumanchi SA: Angiogenic factors and preeclampsia. Semin Nephrol. 31:33–46. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pratt A, Da Silva Costa F, Borg AJ, Kalionis B, Keogh R and Murthi P: Placenta-derived angiogenic proteins and their contribution to the pathogenesis of preeclampsia. Angiogenesis. 18:115–123. 2015. View Article : Google Scholar | |
|
Helmo FR, Lopes AMM, Carneiro ACDM, Campos CG, Silva PB, Dos Reis Monteiro MLG, Rocha LP, Dos Reis MA, Etchebehere RM, Machado JR and Corrêa RRM: Angiogenic and antiangiogenic factors in preeclampsia. Pathol Res Pract. 214:7–14. 2018. View Article : Google Scholar | |
|
Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kendall RL and Kenneth AT: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 90:10705–10709. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R and Charnock-Jones DS: A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod. 59:1540–1548. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ and North RA: Longitudinal serum concentrations of placental growth factor: Evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 188:177–182. 2003. View Article : Google Scholar | |
|
Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hirashima C, Ohkuchi A, Arai F, Takahashi K, Suzuki H, Watanabe T, Kario K, Matsubara S and Suzuki M: Establishing reference values for both total soluble Fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens Res. 28:727–732. 2005. View Article : Google Scholar | |
|
Azimi-Nezhad M: Vascular endothelial growth factor from embryonic status to cardiovascular pathology. Rep Biochem Mol Biol. 2:59–69. 2014.PubMed/NCBI | |
|
Vincenti V, Cassano C, Rocchi M and Persico G: Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 93:1493–1495. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Maglione D, Guerriero V, Viglietto G, Delli-Bovi P and Persico MG: Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA. 88:9267–9271. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
De Falco S: The discovery of placenta growth factor and its biological activity. Exp Mol Med. 44:1–9. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Park JE, Chen HH, Winer J, Houck KA and Ferrara N: Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem. 269:25646–25654. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Lee ES, Oh MJ, Jung JW, Lim JE, Seol HJ, Lee KJ and Kim HJ: The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia. J Korean Med Sci. 22:94–98. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Roberts JM and Rajakumar A: Preeclampsia and soluble fms-like tyrosine kinase 1. J Clin Endocrinol Metab. 94:2252–2254. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Palmer KR, Kaitu'u-Lino TJ, Hastie R, Hannan NJ, Ye L, Binder N, Cannon P, Tuohey L, Johns TG, Shub A and Tong S: Placental-specific sFLT-1 e15a protein is increased in preeclampsia, antagonizes vascular endothelial growth factor signaling, and has antiangiogenic activity. Hypertension. 66:1251–1259. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hastie R, Brownfoot FC, Pritchard N, Hannan NJ, Cannon P, Nguyen V, Palmer K, Beard S, Tong S and Kaitu'u-Lino TJ: EGFR (epidermal growth factor receptor) signaling and the mitochondria regulate sFlt-1 (soluble FMS-Like tyrosine kinase-1) secretion. Hypertension. 73:659–670. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, et al: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 355:992–1005. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, et al: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 111:649–658. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J and Karumanchi SA: First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 89:770–775. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Gonçalves L, Gomez R, Edwin S and Mazor M: Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 17:3–18. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ and Buhimschi IA: Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol. 192:734–741. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Arai F, Watanabe T, Kario K and Suzuki M: Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res. 30:151–159. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Stepan H, Unversucht A, Wessel N and Faber R: Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 49:818–824. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F and D'anna R: Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand. 87:837–842. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, et al: A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 21:9–23. 2008. View Article : Google Scholar : | |
|
Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S and Suzuki M: Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res. 33:422–427. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B and Stepan H: An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 202:161.e1–161.e11. 2010. View Article : Google Scholar | |
|
Sunderji S, Gaziano E, Wothe D, Rogers LC, Sibai B, Karumanchi SA and Hodges-Savola C: Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: A prospective clinical study. Am J Obstet Gynecol. 202:40.e1–e77. 2010. View Article : Google Scholar | |
|
Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B and Hassan SS: Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med. 24:1187–1207. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R and Karumanchi SA: Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 125:911–919. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Moore AG, Young H, Keller JM, Ojo LR, Yan J, Simas TA and Maynard SE: Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med. 25:2651–2657. 2012. View Article : Google Scholar | |
|
Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, et al: The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 206:58.e1–e8. 2012. View Article : Google Scholar | |
|
Herraiz I, Dröge LA, Gómez-Montes E, Henrich W, Galindo A and Verlohren S: Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. Obstet Gynecol. 124:265–273. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chaiworapongsa T, Romero R, Korzeniewski SJ, Cortez JM, Pappas A, Tarca AL, Chaemsaithong P, Dong Z, Yeo L and Hassan SS: Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med. 27:132–144. 2014. View Article : Google Scholar : | |
|
Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS, Verlohren S, Perschel FH, Arany Z, Lim KH, et al: Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy. 32:189–201. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gómez-Arriaga PI, Herraiz I, López-Jiménez EA, Escribano D, Denk B and Galindo A: Uterine artery Doppler and sFlt-1/PlGF ratio: Prognostic value in early-onset pre-eclampsia. Ultrasound Obstet Gynecol. 43:525–532. 2014. View Article : Google Scholar | |
|
Garcia-Tizon Larroca S, Tayyar A, Poon LC, Wright D and Nicolaides KH: Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks' gestation. Fetal Diagn Ther. 36:9–17. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F, Galindo A, Schoofs K, et al: New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 63:346–352. 2014. View Article : Google Scholar | |
|
Schoofs K, Grittner U, Engels T, Pape J, Denk B, Henrich W and Verlohren S: The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med. 42:61–68. 2014. View Article : Google Scholar | |
|
Zhang J, Klebanoff MA and Roberts JM: Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet Gynecol. 97:261–267. 2001.PubMed/NCBI | |
|
No authors listed. ACOG practice bulletin no. 202: Gestational hypertension and preeclampsia. Obstet Gynecol. 133:12019. | |
|
Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC and Giguère Y: Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-analysis. Obstet Gynecol. 116:402–414. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
National Institute for Health and Care Excellence (NICE): PlGF-based testing to help diagnose suspected preterm pre-eclampsia. https://www.nice.org.uk/guidance/dg49. Accessed July 27, 2022 | |
|
Dröge LA, Perschel FH, Stütz N, Gafron A, Frank L, Busjahn A, Henrich W and Verlohren S: Prediction of preeclampsia-related adverse outcomes with the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor)-ratio in the clinical routine: A real-world study. Hypertension. 77:461–471. 2021. View Article : Google Scholar | |
|
Hughes RCE, Phillips I, Florkowski CM and Gullam J: The predictive value of the sFlt-1/PlGF ratio in suspected preeclampsia in a New Zealand population: A prospective cohort study. Aust N Z J Obstet Gynaecol. 63:34–41. 2023. View Article : Google Scholar | |
|
Hund M, Allegranza D, Schoedl M, Dilba P, Verhagen-Kamerbeek W and Stepan H: Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): Study protocol. BMC Pregnancy Childbirth. 14:3242014. View Article : Google Scholar : PubMed/NCBI | |
|
Zeisler H, Llurba E, Chantrain F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, et al: Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. New Engl J Med. 374:13–22. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hund M, Verhagen-Kamerbeek W, Reim M, Messinger D, van der Does R and Stepan H: Influence of the sFlt-1/PlGF ratio on clinical decision-making in women with suspected preeclampsia-the PreOS study protocol. Hypertens Pregnancy. 34:102–115. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Klein E, Schlembach D, Ramoni A, Langer E, Bahlmann F, Grill S, Schaffenrath H, van der Does R, Messinger D, Verhagen-Kamerbeek WD, et al: Influence of the sFlt-1/PlGF ratio on clinical decision-making in women with suspected preeclampsia. PLoS One. 11:e01560132016. View Article : Google Scholar : PubMed/NCBI | |
|
Perales A, Delgado JL, de la Calle M, García-Hernández JA, Escudero AI, Campillos JM, Sarabia MD, Laíz B, Duque M, Navarro M, et al: sFlt-1/PlGF for prediction of early-onset pre-eclampsia: STEPS (study of early pre-eclampsia in Spain). Ultrasound Obstet Gynecol. 50:373–382. 2017. View Article : Google Scholar | |
|
Herraiz I, Simón E, Gómez-Arriaga PI, Quezada MS, García-Burguillo A, López-Jiménez EA and Galindo A: Clinical implementation of the sFlt-1/PlGF ratio to identify preeclampsia and fetal growth restriction: A prospective cohort study. Pregnancy Hypertens. 13:279–285. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sabriá E, Lequerica-Fernández P, Lafuente-Ganuza P, Eguia-Ángeles E, Escudero AI, Martínez-Morillo E, Barceló C and Álvarez FV: Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1/placental growth factor ratio >38 improves prediction of pre-eclampsia requiring delivery within 1 week: A longitudinal cohort study. Ultrasound Obstet Gynecol. 51:758–767. 2018. View Article : Google Scholar | |
|
Lafuente-Ganuza P, Lequerica-Fernandez P, Carretero F, Escudero AI, Martinez-Morillo E, Sabria E, Herraiz I, Galindo A, Lopez A, Martinez-Triguero ML and Alvarez FV: A more accurate prediction to rule in and rule out pre-eclampsia using the sFlt-1/PlGF ratio and NT-proBNP as biomarkers. Clin Chem Lab Med. 58:399–407. 2020. View Article : Google Scholar | |
|
Sovio U, White IR, Dacey A, Pasupathy D and Smith GCS: Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the pregnancy outcome prediction (POP) study: A prospective cohort study. Lancet. 386:2089–2097. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zeisler H, Llurba E, Chantraine FJ, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, et al: Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: Ruling out pre-eclampsia for up to 4 weeks and value of retesting. Ultrasound Obstet Gynecol. 53:367–375. 2019. View Article : Google Scholar : | |
|
Bian X, Biswas A, Huang X, Lee KJ, Li TK, Masuyama H, Ohkuchi A, Park JS, Saito S, Tan KH, et al: Short-term prediction of adverse outcomes using the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor) ratio in Asian women with suspected preeclampsia. Hypertension. 74:164–172. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cerdeira AS, O'Sullivan J, Ohuma EO, Harrington D, Szafranski P, Black R, Mackillop L, Impey L, Greenwood C, James T, et al: Randomized interventional study on prediction of preeclampsia/eclampsia in women with suspected preeclampsia: INSPIRE. Hypertension. 74:983–990. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cerdeira AS, O'Sullivan J, Ohuma EO, James T, Papageorghiou AT, Knight M and Vatish M: Ruling out preeclampsia in the next 4 weeks using a soluble fms-like tyrosine kinase 1/placental growth factor ratio ≤38: Secondary analysis of the interventional study on prediction of preeclampsia/eclampsia in women with suspected preeclampsia. Am J Obstet Gynecol. 226:443–445. 2022. View Article : Google Scholar | |
|
Perry H, Binder J, Kalafat E, Jones S, Thilaganathan B and Khalil A: Angiogenic marker prognostic models in pregnant women with hypertension. Hypertension. 75:755–761. 2020. View Article : Google Scholar | |
|
Peguero A, Fernandez-Blanco L, Mazarico E, Benitez L, Gonzalez A, Youssef L, Crispi F, Hernandez S and Figueras F: Added prognostic value of longitudinal changes of angiogenic factors in early-onset severe pre-eclampsia: A prospective cohort study. BJOG. 128:158–165. 2021. View Article : Google Scholar | |
|
Dathan-Stumpf A, Czarnowsky V, Hein V, Andraczek T and Stepan H: Real-world data on the clinical use of angiogenic factors in pregnancies with placental dysfunction. Am J Obstet Gynecol. 226(2S): S1037–S1047.e2. 2022. View Article : Google Scholar | |
|
Kifle MM, Dahal P, Vatish M, Cerdeira AS and Ohuma EO: The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: A secondary analysis of data from the INSPIRE trial. BMC Pregnancy Childbirth. 22:5202022. View Article : Google Scholar : PubMed/NCBI | |
|
Chaemsaithong P, Sahota DS and Poon LC: First trimester preeclampsia screening and prediction. Am J Obstet Gynecol. 226(2S): S1071–S1097.e2. 2022. View Article : Google Scholar | |
|
Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Peguero A, Dominguez C and Gratacos E: Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy. Fetal Diagn Ther. 35:258–266. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Dominguez C, Llurba E and Gratacós E: First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenat Diagn. 35:183–191. 2015. View Article : Google Scholar | |
|
Lamain-de Ruiter M, Kwee A, Naaktgeboren CA, Louhanepessy RD, De Groot I, Evers IM, Groenendaal F, Hering YR, Huisjes AJM, Kirpestein C, et al: External validation of prognostic models for preeclampsia in a Dutch multicenter prospective cohort. Hypertens Pregnancy. 38:78–88. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tsiakkas A, Mendez O, Wright A, Wright D and Nicolaides KH: Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia. Ultrasound Obstet Gynecol. 47:478–483. 2016. View Article : Google Scholar | |
|
Diguisto C, Piver E, Gouge AL, Eboue F, Vaillant CL, Maréchaud M, Goua V, Giraudeau B and Perrotin F: First trimester uterine artery Doppler, sFlt-1 and PlGF to predict preeclampsia in a high-risk population. J Matern Fetal Neonatal Med. 30:1514–1519. 2017. View Article : Google Scholar | |
|
Verlohren S, Brennecke SP, Galindo A, Karumanchi SA, Mirkovic LB, Schlembach D, Stepan H, Vatish M, Zeisler H and Rana S: Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens. 27:42–50. 2022. View Article : Google Scholar | |
|
Dathan-Stumpf A, Rieger A, Verlohren S, Wolf C and Stepan H: sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation. PLoS One. 17:e02634432022. View Article : Google Scholar : PubMed/NCBI |
